Pharmacokinetics of Antisense Oligonucleotides
作者:
Sudhir Agrawal,
Jamal Temsamani,
Wayne Galbraith,
Jinyan Tang,
期刊:
Clinical Pharmacokinetics
(ADIS Available online 1995)
卷期:
Volume 28,
issue 1
页码: 7-16
ISSN:0312-5963
年代: 1995
出版商: ADIS
数据来源: ADIS
摘要:
Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases.Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes. Administration of a single dose of the phosphorothioate (S-oligonucleotide) in animals by the intravenous route reveals biphasic plasma elimination. An initial short half-life (0.53 to 0.83 hours) represents distribution out of the plasma compartment and a second long half-life (35 to 50 hours) represents elimination from the body. This elimination half-life was similar when the oligonucleotide was administered subcutaneously. In contrast, methylphosphonate oligonucleotides have an elimination half-life of 17 minutes in mice.S-Oligonucleotide was distributed into most of organs of rats and mice. Liver and kidney were the 2 organs with highest uptake of the oligonucleotide. The S-oligonucleotide was primarily excreted in urine. Up to 30% was excreted in the first 24 hours.Repeated daily intravenous injections of a 25-mer S-oligonucleotide into rats showed that the concentrations in the plasma are at steady-state during the 8 days' administration.The data represented here support the potential utility of phosphorothioate and methylphosphonate oligonucleotides as therapeutic agentsin vivo.
点击下载:
PDF
(3846KB)
返 回